Cerebrolysin 30mg

Cerebrolysin 30 mg is a lyophilized peptide-based research preparation supplied exclusively for scientific investigation and controlled laboratory experimentation.

For research use only — not for human or veterinary use.

 

Product Overview

Cerebrolysin is a complex peptide-based research preparation used in laboratory investigations involving peptide mixtures, protein-derived compounds, cellular signalling and biochemical research models.

Unlike research compounds consisting of a single defined peptide sequence, Cerebrolysin represents a complex peptide-based preparation. This makes protein content, microbiological quality, endotoxin analysis and elemental impurity screening particularly relevant parameters when evaluating the analytical characteristics of the research material.

This preparation is supplied as 30 mg of lyophilized Cerebrolysin in a sealed research vial.

Independent third-party laboratory analysis of this production batch confirmed a total protein content of 98.33 percent using a modified Biuret method.

The same analytical programme demonstrated bacterial endotoxin levels below 0.001 EU/mg, while microbiological testing reported 0 CFU/g for both total aerobic microbial count and total yeast and mold count.

Comprehensive elemental impurity screening additionally found arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below the laboratory reporting threshold of 0.001 ppm.

These independently generated analytical results provide researchers with detailed batch-specific documentation and traceability for this Cerebrolysin research preparation.

 

Peptide Overview

Cerebrolysin is a complex peptide-based research preparation rather than a conventional single-sequence synthetic peptide.

Within experimental research environments, complex peptide preparations may be investigated in relation to peptide composition, protein-derived fractions, biochemical interactions, cellular response pathways and molecular signalling systems.

Because Cerebrolysin contains a complex mixture rather than one isolated molecular species, its analytical characterisation differs from that commonly applied to individual synthetic peptides.

For this reason, the current Grail Formula production batch has been independently evaluated using total protein content analysis together with microbiological testing, bacterial endotoxin analysis and elemental impurity screening.

These analytical approaches provide researchers with relevant batch-specific information regarding the composition and laboratory quality characteristics of the tested research material.

 

Historical Background and Scientific Context

Peptide and protein-derived preparations have long formed part of biochemical and molecular research investigating how complex biological fractions interact within experimental cellular systems.

Advances in analytical chemistry and microbiological testing have significantly improved the ability to characterise complex research preparations and evaluate manufacturing consistency.

Analytical methods such as protein-content determination, bacterial endotoxin testing, microbial enumeration and elemental impurity screening allow laboratories to evaluate important quality characteristics of peptide-based research preparations.

Cerebrolysin continues to be investigated within experimental research involving peptide biology, biochemical interactions and cellular laboratory models.

 

Mechanistic Focus in Research

Within controlled laboratory environments, Cerebrolysin may be investigated as a complex peptide-based preparation in experimental models involving molecular and cellular processes.

Research investigations may explore:

• Complex peptide and protein-derived fractions
• Peptide-mediated cellular signalling
• Biochemical interaction pathways
• Cellular response mechanisms
• Molecular communication systems
• Comparative peptide-preparation research
• Controlled in vitro biochemical investigations

These research areas relate exclusively to experimental laboratory investigation and do not imply diagnostic, therapeutic or clinical applications.

 

Analytical Verification (COA)

Each Grail Formula production batch is supported by independent analytical documentation designed to provide researchers with transparent batch-specific quality information.

Analytical testing for this Cerebrolysin batch was performed by Liquilabs s.r.o. Czechia.

The analytical programme included total protein content determination, bacterial endotoxin testing, microbiological analysis, elemental impurity screening and mass spectrometry identity screening.

Batch: GF-CERE30-B241

• Declared Product: Cerebrolysin 30 mg
• Total Protein Content: 98.33 %
• Analytical Method: Modified Biuret Method
• Bacterial Endotoxins: below 0.001 EU/mg
• Total Aerobic Microbial Count: 0 CFU/g
• Total Yeast and Mold Count: 0 CFU/g
• Arsenic: below 0.001 ppm
• Cadmium: below 0.001 ppm
• Mercury: below 0.001 ppm
• Lead: below 0.001 ppm
• Nickel: below 0.001 ppm
• Vanadium: below 0.001 ppm
• Cobalt: below 0.001 ppm

The total protein content result of 98.33 percent was determined using a modified Biuret method, with the laboratory reporting an uncertainty of ±1.97 percent.

Microbiological testing demonstrated 0 CFU/g for total aerobic microbial count and 0 CFU/g for total yeast and mold count.

Bacterial endotoxin testing returned a result below 0.001 EU/mg, compared with the laboratory’s stated acceptable range of 0–0.5 EU/mg.

Elemental impurity screening found all seven reported elements below 0.001 ppm, providing additional analytical documentation of the batch’s elemental impurity profile.

 

Research Applications

Within controlled laboratory environments, Cerebrolysin may be utilised in experimental models designed to investigate complex peptide preparations, biochemical interactions and cellular research systems.

Examples of research applications include:

• Complex peptide preparation research
• Protein-derived compound investigations
• Cellular signalling studies
• Biochemical pathway research
• Molecular interaction investigations
• Comparative peptide research
• Controlled in vitro laboratory studies

These applications are intended exclusively for scientific and laboratory investigation.

 

Grail Formula Quality

Every Grail Formula research compound is supported by batch-specific analytical documentation designed to provide researchers with transparent information about the material supplied.

For this Cerebrolysin production batch, independent testing included:

• Total protein content determination
• Modified Biuret analysis
• Bacterial endotoxin testing
• Total aerobic microbial count
• Total yeast and mold count
• Elemental impurity screening
• Mass spectrometry identity screening
• Batch-specific traceability

Independent laboratory analysis provides researchers with analytical information relating directly to the tested production batch rather than relying solely on general product specifications.

This approach supports transparency, traceability and consistency across Grail Formula research compounds.

 

When You Choose Grail Formula

When selecting Grail Formula, researchers receive research compounds supported by transparent, batch-specific independent analytical documentation.

For Cerebrolysin 30 mg batch GF-CERE30-B241, independent analysis was performed by Liquilabs s.r.o. Czechia and the Certificate of Analysis was published on 15 August 2026.

The Certificate of Analysis documents total protein content, bacterial endotoxin levels, microbiological results, elemental impurity screening and mass spectrometry identity screening.

This batch-specific testing approach provides researchers with independently generated analytical information and traceability to the tested sample.

 

Research Use Limitation

• Used solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not permitted for clinical administration
• For research use only

• Independently analysed by Liquilabs s.r.o. Czechia
• 98.33 % total protein content confirmed by modified Biuret analysis
• Bacterial endotoxin level below 0.001 EU/mg
• Total aerobic microbial count: 0 CFU/g
• Total yeast and mold count: 0 CFU/g
• Arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm
• Batch-specific independent analytical verification
• 30 mg lyophilized research preparation
• Complete COA traceability for batch GF-CERE30-B241
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.